Sema4 Natalis
Sema4 has launched Natalis, a supplemental newborn screening test designed to detect 193 childhood-onset diseases or disorders. In the US, newborns are typically screened for 34 health conditions on the recommended uniform screening panel, but the conditions vary by state and represent only a fraction of the genetic diseases that can manifest in a child's first decade, Sema4 noted. As a supplemental test, Natalis screens for more than five times the number of genetic diseases than a state's standard hospital test, the company said. Every Sema4 Natalis order also includes a pharmacogenetic analysis of how a baby is likely to respond to 38 medications commonly prescribed at an early age. The test uses DNA sequencing analysis, and sample collection can be performed at home with a cheek swab, the company said.
Cofactor Genomics Paragon
Cofactor Genomics has launched Paragon, a cancer type-agnostic solid tumor immune-profiling assay that uses a proprietary database of immune reference signatures to interrogate immune activity associated with disease or therapy response. For example, the assay can differentiate cells such as M1 and M2 macrophages and can report cancer-specific expression signals from genes including PD-1, PD-L1, and CTLA4. The assay requires only two FFPE tissue sections for analysis and can accommodate any solid tumor specimen, with expression databases pre-built for more than 25 different cancer types, Cofactor said.
Personalis ImmunogenomicsID and NeoantigenID
Personalis has launched ImmunogenomicsID, which combines DNA and RNA sequencing data to generate an immunogenomic profile of a tumor and its microenvironment. The product is designed to help identify biomarkers and signatures that can impact patient response to cancer immunotherapies. It is a new component and extension of the company's existing ACE ImmunoID Platform, which combines genome-scale sequencing with data analytics for broad tumor immunogenomic characterization.
For more new products and services, please visit the New Products page on our website.